Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0023418 (leukemia)
 93,477 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The antitumor effects of weekly iv injections of 1.0 mg BCG and/or sc injections of 10(7) irradiated leukemia cells were studied in an isogeneic, transplantable lymphoid leukemia in the C57BL/6 mouse. The injections were started at day 1 after ip inoculation of 10(5) leukemia cells. BCG prolonged the survival time of most animals and cured 22%. BCG plus irradiated cells cured only about 10% of the mice, and irradiated cells alone had no curative effect. Individual tumor-bearing mice in the various experimental groups were examined with respect to ascites tumor cell number; complement-dependent cytotoxic antibodies in sera; direct and antibody-dependent cytotoxicity to tumor cells of lymphoid cells from peritoneal fluid, the spleen, and peripheral lymph nodes; and the cytology of ascites, the spleen, and lymph nodes. Only the antibody-dependent lymphocyte-mediated cytotoxicity (ADLMC) was correlated with the ascites tumor cell number, since the ADLMC was high only in mice with a tumor cell number less than that of the controls. Furthermore, since mice with a low tumor cell number had predominantly only lymphocytes as the nonmalignant cell type in their peritoneal fluid, ADLMC may have had an important role in BCG-induced control of tumor growth.
 ...
PMID:Cellular and humoral immunity to leukemia cells in BCG-induced growth control of a murine leukemia. 90 1

Inoculation i.p. of C57BL/6 mice with FBL-3 cells, a syngeneic Friend virus-induced leukemia, results in progressive growth of ascitic tumors; in contrast, s.c. inoculation of FBL-3 cells produces transient, localized tumor growth; the recipients are then subsequently resistant to further i.p. challenge of this tumor. Experiments were performed to study the effects of humoral factors that might be present in the ascitic fluid and that could affect the growth of the tumors and the host immune response. It was found that ascitic fluids obtained from various murine tumors could indeed promote the s.c. growth of FBL-3 cells. Furthermore, administration of these ascitic fluids was found to suppress the induction of both the primary and secondary cell-mediated cytotoxic responses to FBL-3 cells in vivo and in vitro and to inhibit the effector phase of these cell-mediated cytotoxic reactions in vitro. These studies indicate that the ascitic fluids obtained from tumor-bearing hosts contain humoral factors that can promote tumor growth and suppress immune responses.
 ...
PMID:Humoral regulation of cell-mediated immunity to syngeneic tumor. 95 95

The effect of Rauscher Leukemia Virus (MuLV-R) infection on the lipid composition of mouse spleen from BALB/c mice was investigated. Drastic changes in the lipid composition of the spleen as a result of tumor growth induced by the virus could be demonstrated at 21 days after infection. The molar ratio of cholesterol to phospholipids was found to be low, while a shift within the choline containing phospholipid classes resulted into a lower sphingomyelin and a higher phosphatidyl choline content of the MuLV-R infected spleen. The cholesterol ester content increased more than two-fold during tumor growth, and shifts in the fatty acid patterns of the lipids were demonstrated.
 ...
PMID:Changes in the cholesterol and phospholipid content of mouse spleen after Raucscher leukemia virus infection. 99 50

Aqueous zinc acetate injected ip prevented tumor growth in 50-70% of BDF male mice previously inoculated ip with L1210 leukemia cells. However, aqueous zinc acetate injected sc did not prevent tumor growth in AKR/J mice inoculated im with BW5147 lymphatic leukemia cells. In the latter mice, only a small but statistically significant increase in mean survival was noted.
 ...
PMID:Effect of zinc administration on the growth of L1210 and BW5147 tumors in mice. 100 17

L1210 leukemia cells grew progressively and caused tumor deaths in all recipient mice. However, when these cells had been treated with Vibrio cholerae neuraminidase (VCN) prior to injection, tumor deaths did not occur. Both untreated and VCN-treated L1210 cells elicited a humoral response, as manifested by an increasing percent of cells in the spleen and peritoneal cavity, with various types of membrane-associated immunoglobulins. Progressive tumor growth was associated with a large percent of peritoneal exudate (PE) cells bearing membrane-associated IgG, a late increase in the percent of PE cells with IgG, and only a small percent of PE cells with IgM on their surfaces. Conversely, PE cells from mice given VCN-treated L1210 cells were characterized by a small percent with IgG, an early increase in percent of cells with IgG, and a large percent with membrane-associated IgM. An injection of VCN-treated L1210 cells into mice with progressively growing L1210 tumors caused frequent tumor remissions, with a corresponding alteration of the ongoing humoral responses. Both the degree of alteration and the number of cures depended on the tumor burden at the time VCN-treated tumor cells were injected. The humoral response in mice with tumor remission following immunization was comparable to the response detected after an injection of VCN-treated cells only.
 ...
PMID:Humoral reponse to neuraminidase-treated tumor cells. 103 96

N-(Phosphonacetyl)-L-aspartate (PALA) is an analog of the transition state for the aspartate transcarbamylase reaction and has been reported previously to be a potent and specific inhibitor of de novo pyrimidine nucleotide biosynthesis. It is now shown that PALA has considerable antitumor activity against certain transplantable tumors in mice. PALA, unlike other antimetabolites, was less effective against ascitic leukemias than against two solid tumors, B16 melanoma and Lewis lung carcinoma. Another solid tumor, Ridgway osteogenic sarcoma, which is sensitivie to many established chemotherapeutic agents, did not respond to PALA. Daily or intermittent treatment with PALA did not significantly increase the life-span of mice bearing i.p. leukemia L1210. The survival time of mice bearing i.p. P388 leukemia was prolonged by PALA treatment by up to 64%. In a number of experiments mice bearing i.p. B16 melanoma survived 77 to 86% longer than did controls when treated with PALA (490 mg/kg) on Days 1, 5, and 9. Lewis lung carcinoma, a tumor refractory to most established antineoplastic agents, was highly sensitive to PALA. Treatment on Days 1, 5, and 9 following s.c. implantation of Lewis lung carcinoma was curative to 50% of the mice. If treatment was delayed until s.c. Lewis lung tumors had reached about 500 mg, PALA neither cured the mice nor produced significant tumor regression. However, extensive delay of tumor growth and prolongation of survival were still observed.
 ...
PMID:Antitumor activity of N-(phosphonacetyl)-L-aspartic acid, a transition-state inhibitor of aspartate transcarbamylase. 106 66

Lewis lung adenocarcinoma growth was retarded by the oral administration of delta9-tetrahydrocannabinol (delta9-THC), delta8-tetrahydrocannabinol (delta8-THC), and cannabinol (CBN), but not cannabidiol (CBD). Animals treated for 10 consecutive days with delta9-THC, beginning the day after tumor implantation, demonstrated a dose-dependent action of retarded tumor growth. Mice treated for 20 consecutive days with delta8-THC and CBN had reduced primary tumor size. CBD showed no inhibitory effect on tumor growth at 14, 21, or 28 days. Delta9-THC, delta8-THC, and CBN increased the mean survival time (36% at 100 mg/kg, 25% at 200 mg/kg, and 27% at 50 mg/kg, respectively), whereas CBD did not. Delta9-THC administered orally daily until death in doses of 50, 100, or 200 mg/kg did not increase the life-spans of (C57BL/6 times DBA/2)F1 (BDF1) mice hosting the L1210 murine leukemia. However, delta9-THC administered daily for 10 days significantly inhibited Friend leukemia virus-induced splenomegaly by 71% at 200 mg/kg as compared to 90.2% for actinomycin D. Experiments with bone marrow and isolated Lewis lung cells incubated in vitro with delta9-THC and delta8-THC showed a dose-dependent (10(-4)-10(-7)) inhibition (80-20%, respectively) of tritiated thymidine and 14C-uridine uptake into these cells. CBD was active only in high concentrations (10(-4)).
 ...
PMID:Antineoplastic activity of cannabinoids. 115 36

Twenty-seven new derivatives of the 3-N,N-bis-(2-chlorethyl)-amino-4-methyl-benzoic-acid were synthesized and pharmacologically examined. The compounds showed to be highly active in the in vitro-vivo screening models (Crocker sarcoma 180, Sa-180; Friend virus leukemia, FVL) but less active in the in vivo screening models (leukemia L-1210; L-1210; Nemeth-Kellner lympho-sarcoma, NKL). The in vivo tumor growth inhibitions show that this class of compounds has possibilities for further improvement.
 ...
PMID:[Aromatic N-mustard compounds. 1. Derivatives of 3-N, N-bis-(2-chlorethyl)amino-4-methylbenzoid acid]. 117 61

Levamisole and tetramisole had no antitumor effect against the following transplantable syngeneic murine tumors: L1210 leukemia, P388 leukemia, B16 melanoma, Madison 109 lung tumor, and Lewis lung carcinoma. In the Lewis lung carcinoma system there was no effect on primary tumor growth, metastasis, or survival. Tetramisole had a variable effect on the growth of rhabdomyosarcomas and the survival of BALB/c mice following intramuscular inoculation of Moloney sarcoma virus. In two experiments treatment with tetramisole either prior to or following inoculation of Moloney sarcoma virus increased the number of mice with tumor regression as opposed to progressive tumor growth, incrneased the number of long-term survivors, and prolonged the lifespan of mice that died of tumor. In two further tests neither levamisole nor tetramisole had an effect in this system. In mice immunosuppressed with cyclophosphamide prior to virus inoculation, there was not effect of treatment with levamisole or tetramisole.
 ...
PMID:Effects of levamisole (NSC-177023) and tetramisole (NSC-102063) in experimental tumor systems. 117 64

W/Fu rats were injected subcutaneously with low numbers of cells from the Gross leukemia virus-induced lymphoma, (C58NT)D, which induced transient tumor growth and regression (regressors), or with high numbers of tumor cells resulting in progressive tumor growth (progressors). Spleen cells from regressors had a significant reactivity in the mixed leukocyte tumor cell interation (MLTI), while spleen cells from progressors were unresponsive. Similarly, the responses to the non-specific mitogens, phytohemagglutinin and concanavalin A, were suppressed in spleen-cell cultures of progressors. Passage of spleen cells from progressors over rayon adherence columns or pretreatment with an iron/magnet technique resulted in almost complete restoration of MLTI and mitogen responses. Addition of spleen cells from progressors depressed the MLTI of spleen cells from regressors and the mitogen reactivity of normal spleen cells. Serum from progressors also suppressed MLTI and mitogen reactivity. These data indicate that, in spleens of rats bearing progressively growing tumors, suppressor cells can be demonstrated which inhibit specific reactivity to tumor-associated antigens and non-specific reactivity to mitogens. The presence of suppressor cells or of inhibitory factors in the serum may contribute to the immunosuppression frequently observed in tumor-bearing hosts.
 ...
PMID:Inhibition of in vitro lymphoproliferative responses to tumor-associated antigens by suppressor cells from rats bearing progressively growing Gross leukemia virus-induced tumors. 117


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>